No Detail Found!

Permanent Bilateral Sensorineural Hearing Loss in a Patient Treated with Nilotinib for Chronic Myeloid Leukemia: A Case Report

Author(s)
Ayesha Saleem Postgraduate Resident, Department of Internal Medicine, KRL Hospital,Islamabad,Pakistan
Abstract
Introduction of tyrosine kinase inhibitors was a great milestone towards treatment of Chronic Myeloid Leukemia (CML). Increment in specificity for inhibition of tyrosine kinase enzyme in leukemic cells led to the development of new BCR-ABL fusion protein inhibitors. The anticipation of improved efficacy of drugs and decreased side effects profile was met with encouraging response when Nilotinib as a next step to Imatinib was introduced. However, side effects did occur with nilotinib. Here is a case report of a patient with CML, treated with nilotinib, who later developed an undescribed side effect of permanent sensorineural hearing loss. We could not find any literature support regarding occurrence of this side effect with very potent drug nilotinib. We have to bear in mind that the fantasy of superior specificity and efficacy of nilotinib as compared to imatinib could not prevent it from causing a side effect that had already been described in literature for imatinib.
Publication Details
Page(s) 107-109
DOI DOI not available
Published Journal: Journal of Pioneering Medical Sciences, Volume: 6, Issue: 4, Year: 2016

Request the full text from PASTIC

Keywords
Tyrosine Kinase Inhibitors, sensorineural hearing loss, Chronic myeloid leukemia, Nilotinib
References
Faderl S,Talpaz M,Estrov Z,Kantarjian HM .1999 .Chronic myelogenous leukemia: biology and therapy. Annals of Internal Medicine, 131(3) : 207-219.
Siegel JR,Xu J,Ward E .2010 .. Cancer Journal for Clinicians, 60(5) : 277-300.
Tefferi A . .Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. , : .
.2006 .. Hematology Am Soc of Hematol Educ Program, : 240-5.
.2016 .. 2016 [cited 4 June, : .
Available ,Gambacorti-Passerini C,Antolini L,Mahon F,Guilhot F,Deininger M,Fava C .2011 .Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib. JNCI Journal of the National Cancer Institute, 103(7) : 553-561.
Kantarjian H,Giles F,Gattermann N,Bhalla K,Alimena G,Palandri F .2007 .Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood, 110(10) : 3540-3546.
Weisberg E,Manley P,Cowan-Jacob S,Hochhaus A,Griffin J .2007 .Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nature Reviews Cancer, 7(5) : 345-356.
Common Side Effects of Tasigna Capsules (Nilotinib Capsules) Drug Center - RxList ,- ,Lin H,Roberts D,Kay J,Stankovic K.,Sensorineural Hearing K.,Surgery Neck .2011 .Loss following Imatinib (Gleevec) Administration. html 10, 146(2) : 335-337.
Üsküdar Teke H,Akay O,Gören Şahin D,Karagülle M,Gündüz E,Andıç N. Pleural,Effusion N. Pleural .2014 .. A Rare Side Effect of Nilotinib-A Case Report. Case Reports in Medicine, : 1-3.
Masiello D,Gorospe G,Yang A .2009 .The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib. Journal of Hematology & Oncology, 2(1) : 46.
Fritzsch B,Pirvola U,Ylikoski J .1999 .Making and breaking the innervation of the ear: neurotrophic support during ear development and its clinical implications. Cell and Tissue Research, 295(3) : 369-382.
Petit C .1996 .Genes responsible for human hereditary deafness: symphony of a thousand. Nature Genetics, 14(4) : 385-391.
0

Citations

0

Downloads

10

Views